Evaluation of the effect of sorafenib using serum NX-des-Î³-carboxyprothrombin in patients with hepatocellular carcinoma.

Miyahara, Koji; Nouso, Kazuhiro; Morimoto, Yuki; Tomoda, Takeshi; Kobayashi, Sayo; Takeuchi, Yasuto; Hagihara, Hiroaki; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Yamamoto, Kazuhide

Miyahara, Koji; Nouso, Kazuhiro; Morimoto, Yuki; Tomoda, Takeshi; Kobayashi, Sayo; Takeuchi, Yasuto; Hagihara, Hiroaki; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Yamamoto, Kazuhide.

Afiliação

Miyahara K; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

Hepatol Res ; 43(10): 1064-70, 2013 Oct.

Article em En | MEDLINE | ID: mdl-23347420

Palavras-chave

NX-des-Î³-carboxyprothrombin; des-Î³-carboxyprothrombin; hepatocellular carcinoma; sorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Hepatol Res Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google